Secondary hyperparathyroidism is excessive PTH secretion in response to chronic hypocalcemia (commonly from chronic kidney disease), while tertiary hyperparathyroidism is autonomous parathyroid hyperplasia that persists after prolonged secondary stimulation, causing hypercalcemia even when the original stimulus is corrected.

Secondary & Tertiary Hyperparathyroidism

Let's break down the terminology first to understand exactly what we're dealing with.

Hyperparathyroidism (HPT) → "hyper" = excessive, "para" = beside, "thyroid" = thyroid gland, "-ism" = condition. So: a condition of excessive hormone secretion from the glands beside the thyroid.
Parathyroid hormone (PTH) is the key hormone — its job is to raise serum calcium and lower serum phosphate.

Now, the classification hinges on why the parathyroid glands are overactive:

Type	Definition	Core Mechanism
Primary HPT	Autonomous PTH secretion from an intrinsic parathyroid lesion (adenoma, hyperplasia, carcinoma)	The gland itself is abnormal → secretes PTH regardless of calcium level
Secondary HPT	Physiological, compensatory ↑PTH secretion in response to chronic hypocalcaemia and/or hyperphosphataemia ^[1]^[2]	The glands are reactive — they are doing their job, but the stimulus (low Ca²⁺) never goes away
Tertiary HPT	Persistent autonomous hypercalcaemic hyperparathyroidism that develops after prolonged secondary HPT — classically after renal replacement therapy (transplantation) where the original stimulus has been removed but the glands have become autonomous ^[2]^[3]	Prolonged stimulation → parathyroid gland hyperplasia → nodular transformation → monoclonal adenomatous change → glands no longer respond to calcium feedback

The Key Conceptual Distinction

Secondary HPT = appropriate PTH response to an inappropriate environment (chronic hypocalcaemia/hyperphosphataemia). Calcium is usually low or low-normal.
Tertiary HPT = inappropriate PTH response in a corrected environment (post-transplant or after prolonged secondary HPT). Calcium is elevated because the glands have become autonomous.
Think of it as a spectrum: secondary HPT is the "physiological extreme," and tertiary HPT is when the glands "cross the line" into autonomy.

2. Epidemiology and Risk Factors

3. Anatomy and Function of the Parathyroid Glands

Understanding the anatomy is crucial for surgery and understanding pathophysiology.

PTH is an 84-amino acid polypeptide. Its sole purpose is to raise serum calcium (and lower phosphate). It acts on three target organs:

Target Organ	Action	Mechanism
Bone	↑ Ca²⁺ release (bone resorption)	Stimulates osteoclasts (indirectly via RANKL on osteoblasts → activates osteoclast precursors)
Kidney	↑ Ca²⁺ reabsorption (DCT)	Upregulates TRPV5 calcium channels in the distal convoluted tubule
	↓ PO₄³⁻ reabsorption (PCT)	Downregulates NaPi-IIa and NaPi-IIc sodium-phosphate cotransporters in proximal tubule → phosphaturia
	↑ 1,25-(OH)₂-D₃ production	Stimulates 1α-hydroxylase in proximal tubule → converts 25-OH-D to active 1,25-(OH)₂-D₃
Gut (indirect)	↑ Ca²⁺ and PO₄³⁻ absorption	Via 1,25-(OH)₂-D₃ which upregulates intestinal calcium-binding protein (calbindin)

Net effect of PTH: ↑ Ca²⁺, ↓ PO₄³⁻ (because the phosphaturic effect outweighs the bone + gut phosphate release)

4. Etiology (Focus on Hong Kong)

Causes of Secondary HPT

The common theme: anything that chronically lowers ionised calcium or raises phosphate.

5. Pathophysiology

This is the most important section to understand deeply. Let's build it from first principles.

Detailed stepwise explanation: ^[4]

Early CKD (GFR < 60 mL/min — Stage 3):
- The kidneys lose their ability to excrete phosphate efficiently → mild hyperphosphataemia
- Phosphate directly binds ionised calcium in blood → ↓ ionised Ca²⁺ (calcium-phosphate precipitation)
- Phosphate also directly stimulates PTH secretion at the parathyroid gland (independent of calcium)
- Phosphate stimulates FGF-23 (fibroblast growth factor 23) secretion from osteocytes and osteoblasts
  - FGF-23 acts on the kidney to increase phosphate excretion (phosphaturic — this is initially compensatory)
  - But FGF-23 also inhibits 1α-hydroxylase → ↓ 1,25-(OH)₂-D₃ production
- Simultaneously, ↓ renal mass → ↓ 1α-hydroxylase activity → ↓ 1,25-(OH)₂-D₃
- ↓ 1,25-(OH)₂-D₃ → ↓ intestinal calcium absorption → further ↓ serum Ca²⁺
- ↓ 1,25-(OH)₂-D₃ also removes the suppressive effect on PTH gene transcription (vitamin D normally directly suppresses PTH mRNA) → more PTH produced
- Net result at this stage: PTH rises to compensate — and actually succeeds in keeping serum Ca and PO₄ relatively normal. But the price paid is elevated PTH and increased bone turnover.
Late CKD (GFR < 20 mL/min — Stage 4–5):
- The compensatory mechanisms decompensate
- ↓↓ GFR → progressive PO₄ retention that overwhelms FGF-23 and PTH → overt hyperphosphataemia
- ↓↓ Renal mass → severely ↓ 1,25-(OH)₂-D₃ → overt hypocalcaemia
- PTH rises further but cannot restore normal Ca and PO₄ levels
- Parathyroid gland hyperplasia becomes established — all 4 glands enlarge
- The elevated Ca × PO₄ product drives metastatic/vascular calcification ^[4]
On Dialysis:
- Dialysis partially corrects phosphate and calcium, but:
  - Phosphate clearance is often inadequate (dietary intake exceeds dialysis clearance)
  - Intermittent nature of haemodialysis means calcium and phosphate fluctuate
  - Secondary HPT often persists or worsens despite dialysis
- Iatrogenic factors can contribute:
  - Calcium-based phosphate binders (e.g., calcium carbonate) → can cause positive calcium balance → contributes to vascular calcification
  - Overtreatment with vitamin D analogues → may excessively suppress PTH → adynamic bone disease (too little bone turnover → fragile bones) ^[4]

FGF-23: The Early Warning Signal

FGF-23 is now recognised as the earliest biochemical abnormality in CKD-MBD — it rises even before PTH or phosphate become abnormal. It's a phosphatonin produced by osteocytes. While initially compensatory (increases phosphate excretion), its inhibition of 1α-hydroxylase is a key driver of the cascade leading to secondary HPT. Think of FGF-23 as the body's first attempt to deal with phosphate retention, but it inadvertently worsens vitamin D status and calcium balance.

6. Classification

Feature	Secondary HPT	Tertiary HPT
Underlying cause	Chronic hypocalcaemia / hyperphosphataemia (usually CKD)	Prolonged secondary HPT → autonomous transformation
Gland behaviour	Reactive (appropriate response)	Autonomous (inappropriate)
Serum calcium	Low or low-normal	Elevated (hypercalcaemia)
Serum phosphate	Usually elevated (in CKD)	Variable (may be normal post-transplant)
PTH	Elevated (appropriately)	Elevated (inappropriately — not suppressed by high Ca)
Gland histology	Diffuse hyperplasia (polyclonal)	Nodular hyperplasia / adenomatous change (monoclonal)
Classic clinical context	CKD Stage 3–5D (on dialysis)	Post-renal transplant (or prolonged dialysis)

The 2006 KDIGO classification uses the TMV system for bone biopsy:

T = Turnover (high vs. low)
M = Mineralisation (normal vs. abnormal)
V = Volume (high vs. low vs. normal)

Pattern	Turnover	Mineralisation	Volume	Association
Osteitis fibrosa cystica	High	Normal	High	Severe secondary/tertiary HPT
Osteomalacia	Low	Abnormal	Low	↓ Vitamin D, aluminium toxicity
Mixed uraemic osteodystrophy	High	Abnormal	Variable	Combination
Adynamic bone disease	Low	Normal	Low	Over-suppression of PTH, diabetes, elderly

7. Clinical Features

7A. Symptoms

Many patients with secondary HPT are asymptomatic — the features of CKD-MBD develop insidiously over years.

Symptom	Pathophysiological Basis
Diffuse bone pain (especially back, hips, lower limbs)	↑PTH → excessive osteoclastic bone resorption → microfractures, periosteal stretching from subperiosteal resorption; also osteomalacia (defective mineralisation) causes deep, aching bone pain
Fractures (fragility fractures — vertebral compression, hip, rib)	Bone weakened by both high turnover disease (osteitis fibrosa → abnormal bone architecture) and osteomalacia (undermineralised bone). In adynamic bone disease, low remodelling also → brittle bone
Proximal myopathy (difficulty rising from chair, climbing stairs)	↓ 1,25-(OH)₂-D₃ → impaired calcium-dependent muscle contraction (vitamin D has direct effects on muscle via VDR) → proximal muscle weakness. Also, hypocalcaemia contributes to neuromuscular dysfunction
Height loss / kyphosis	Vertebral compression fractures from weakened vertebral bodies

Symptom	Pathophysiological Basis
Paraesthesiae (perioral, fingers, toes)	↓ ionised Ca²⁺ → ↓ threshold for nerve depolarisation → spontaneous nerve firing → tingling sensations
Muscle cramps / tetany	Same mechanism — enhanced neuromuscular excitability → involuntary sustained muscle contraction
Carpopedal spasm	Severe hypocalcaemia → tonic spasm of hand (obstetric hand) and foot muscles
Seizures	Severe hypocalcaemia → ↑ neuronal excitability → generalised seizures
Laryngospasm	↓ Ca²⁺ → spasm of laryngeal muscles → stridor — a life-threatening emergency

The classic mnemonic: "Stones, Bones, Moans, Thrones, and Psychic Overtones" ^[5]

Symptom	Pathophysiological Basis
Stones (renal colic, haematuria)	↑ Ca²⁺ → hypercalciuria → calcium oxalate/phosphate stone formation. Also ↑ urinary pH from PTH action promotes calcium phosphate precipitation
Bones (bone pain — see above)	↑ PTH → ↑ osteoclastic resorption → bone pain, fractures
Moans (abdominal pain, constipation, nausea, vomiting, anorexia)	Hypercalcaemia → ↓ smooth muscle contractility (Ca²⁺ stabilises cell membranes → ↓ excitability) → gastroparesis, constipation. Also: pancreatitis (calcium activates trypsinogen in pancreas), peptic ulcer (Ca²⁺ stimulates gastrin secretion)
Thrones (polyuria, polydipsia, dehydration)	↑ Ca²⁺ → inhibits adenylyl cyclase in collecting duct → ↓ cAMP → ↓ aquaporin-2 insertion → nephrogenic diabetes insipidus → polyuria → dehydration → polydipsia ^[5]
Psychic overtones (confusion, lethargy, depression, anxiety, psychosis)	Hypercalcaemia affects neuronal function — exact mechanism multifactorial but includes altered neurotransmitter release and neuronal membrane stabilisation

Symptom	Pathophysiological Basis
Pruritus (itch)	Multifactorial in CKD: metastatic calcium-phosphate deposition in skin, uraemic toxins, histamine release. ↑ Ca × PO₄ product specifically drives cutaneous microprecipitation
Fatigue / malaise	Multifactorial: hypercalcaemia effects on CNS, CKD-associated anaemia, uraemia
Joint pain (pseudogout)	Calcium pyrophosphate crystal deposition in joints → acute inflammatory arthritis. ↑ PTH → ↑ pyrophosphate production → CPPD disease

7B. Physical Signs

Sign	Pathophysiological Basis
Bone tenderness (especially sternum, tibiae, ribs)	Subperiosteal resorption and microfractures cause localised tenderness
Kyphosis / spinal deformity	Vertebral compression fractures
Proximal myopathy (waddling gait, difficulty standing from squat)	Vitamin D deficiency → impaired muscle function (see above)
Growth retardation (in paediatric CKD)	Chronic hypocalcaemia, hyperphosphataemia, and ↓ vitamin D impair growth plate function; ↑ PTH disrupts endochondral ossification → renal rickets

Sign	Pathophysiological Basis
Chvostek's sign (tapping facial nerve → ipsilateral facial muscle twitching)	Enhanced neuromuscular excitability from hypocalcaemia → mechanical stimulation of facial nerve → reflex muscle contraction. Sensitivity ~10–30% (can be positive in normocalcaemic individuals)
Trousseau's sign (inflate BP cuff above systolic for 3 min → carpopedal spasm)	Ischaemia from cuff + hypocalcaemia → enhanced neuromuscular excitability → carpal spasm (more specific than Chvostek's — ~94% specificity)
Prolonged QT interval on ECG	Ca²⁺ is critical for phase 2 (plateau) of the cardiac action potential. ↓ Ca²⁺ → prolonged phase 2 → prolonged QT → risk of Torsades de Pointes

Sign	Pathophysiological Basis
Shortened QT interval on ECG	↑ Ca²⁺ → shortened phase 2 of cardiac action potential
Band keratopathy (corneal calcification — seen on slit lamp)	Calcium phosphate deposition at the medial and lateral limbus of the cornea (where pH is highest — CO₂ escapes from the cornea peripherally → more alkaline → favours CaPO₄ precipitation)
Hypertension	Hypercalcaemia → vasoconstriction (Ca²⁺ enhances vascular smooth muscle contraction) and ↑ renal vascular resistance ^[6]
Dehydration (poor skin turgor, dry mucous membranes)	Nephrogenic DI from hypercalcaemia → polyuria → volume depletion

Sign	Pathophysiological Basis
Calciphylaxis (violaceous, reticular, painful skin lesions → necrotic eschar, especially on thighs, abdomen, buttocks)	Calcification of dermal and subcutaneous arterioles → thrombosis → ischaemic skin necrosis. ↑ Ca × PO₄ product and ↑ PTH are risk factors ^[4]
Tumoral calcinosis (periarticular soft tissue masses)	Massive calcium-phosphate deposits in periarticular tissue when Ca × PO₄ product chronically elevated
Absent peripheral pulses / bruits	Arterial medial calcification (Mönckeberg's) → stiff, non-compressible vessels
Red eyes (conjunctival calcification)	Calcium-phosphate deposition in conjunctiva

Bone scan (99mTc-MDP): may show a superscan pattern — intense symmetric bone activity with diminished renal and soft tissue activity — seen in secondary hyperparathyroidism, renal osteodystrophy, and osteomalacia ^[7]

Plain radiograph findings in secondary/tertiary HPT:

Finding	Explanation
Subperiosteal resorption (radial aspect of middle phalanges — pathognomonic)	PTH-driven osteoclastic resorption occurs at the subperiosteal surface; the radial side of the middle phalanx is the classic site because cortical bone here is thin and resorption is most visible
Salt and pepper skull	Diffuse granular mottling due to trabecular resorption in the calvarium
Brown tumours (cystic lucencies)	Focal collections of osteoclasts, fibrous tissue, and haemosiderin (hence "brown") — represent extreme localised bone resorption
Rugger jersey spine	Alternating bands of sclerosis (dense) and lucency (resorbed) in the vertebral bodies — sclerotic endplates with osteopenic centres
Soft tissue / vascular calcification	Calcium-phosphate deposition in vessel walls, periarticular tissues
Looser zones / pseudofractures (if osteomalacia component)	Radiolucent lines perpendicular to bone cortex — represent unmineralised osteoid at sites of stress

Parameter	Secondary HPT (CKD)	Tertiary HPT
Serum Ca²⁺	↓ or low-normal	↑ (hypercalcaemia)
Serum PO₄³⁻	↑ (due to ↓ renal excretion)	Variable (often normal or ↓ post-transplant because the new kidney excretes PO₄)
PTH	↑ (appropriately)	↑ (inappropriately — not suppressed by ↑ Ca)
25-OH Vitamin D	Often ↓	Variable
1,25-(OH)₂-D₃	↓ (due to ↓ 1α-hydroxylase)	May normalise post-transplant
ALP	↑ (high bone turnover)	↑
FGF-23	↑↑ (early marker)	May normalise post-transplant
Ca × PO₄ product	Often ↑ (> 4.4 mmol²/L²)	Variable

High Yield Summary

Secondary HPT:

Definition: Compensatory ↑PTH in response to chronic hypocalcaemia/hyperphosphataemia — the glands are reactive, not autonomous
Cause: Overwhelmingly CKD (in Hong Kong: DM nephropathy #1) — also vitamin D deficiency, calcium malabsorption
Pathophysiology: ↓GFR → ↓PO₄ excretion + ↓1α-hydroxylase → ↑PO₄, ↓Ca²⁺, ↓1,25-D₃ → ↑PTH → bone resorption, renal osteodystrophy, vascular calcification
FGF-23 rises earliest; PTH rises as compensation fails
Biochemistry: ↑PTH, ↓Ca, ↑PO₄, ↓1,25-D₃
Bone disease: High turnover (osteitis fibrosa cystica, subperiosteal resorption) or low turnover (adynamic bone disease from over-treatment)

Tertiary HPT:

Definition: Persistent autonomous ↑PTH after removal of the original stimulus (classically post-renal transplant) — glands have become autonomous
Mechanism: Prolonged secondary HPT → polyclonal hyperplasia → nodular hyperplasia → monoclonal adenomatous change → ↓CaSR and ↓VDR expression → autonomous PTH secretion
Biochemistry: ↑PTH + ↑Ca²⁺ (the distinguishing feature from secondary HPT)
Clinical features: Hypercalcaemia symptoms (stones, bones, moans, thrones, psychic overtones) + may impair renal graft function

Clinical features of both: bone pain, fractures, proximal myopathy (vitamin D deficiency), pruritus, vascular calcification, calciphylaxis (CKD-MBD spectrum). Secondary HPT → hypocalcaemia signs (Chvostek's, Trousseau's). Tertiary HPT → hypercalcaemia signs.

Key radiological findings: Subperiosteal resorption (pathognomonic), salt and pepper skull, rugger jersey spine, brown tumours, superscan on bone scan.

Active Recall - Secondary & Tertiary HPT: Definition, Epidemiology, Pathophysiology, Clinical Features

Differential Diagnosis of Secondary & Tertiary Hyperparathyroidism

The differential diagnosis here is really about two clinical scenarios: (1) a patient with elevated PTH — what is driving it? and (2) a patient with disordered calcium (hypo- or hypercalcaemia) in the context of CKD or post-transplant — what else could explain the biochemistry?

Let's think about this systematically from first principles.

Detailed Differential Diagnosis

The question here is: Why is the calcium chronically low, driving compensatory PTH secretion?

Differential	How to Distinguish	Key Investigations
CKD (most common cause of secondary HPT)	History of CKD, diabetes, hypertension. Progressive over years. Elevated creatinine, low GFR. Hyperphosphataemia is characteristic	RFT (↑creatinine, ↑urea, ↓eGFR), ↑PO₄, ↓1,25-(OH)₂-D₃, ↑FGF-23
Vitamin D deficiency (dietary, malabsorption, lack of sunlight)	No CKD. Low 25-OH-D is the hallmark. PO₄ may be low/normal (PTH drives phosphaturia, and kidneys are working). Often elderly, institutionalised, dark-skinned, or malabsorption history	25-OH vitamin D (will be low, < 50 nmol/L). Normal RFT. PO₄ normal or ↓
Calcium malabsorption (coeliac disease, post-gastrectomy, chronic pancreatitis, short bowel syndrome)	Malabsorption history, steatorrhoea, weight loss. Low calcium despite adequate diet	Tissue transglutaminase Ab (coeliac), faecal elastase (pancreatic insufficiency), endoscopy with duodenal biopsy
Pseudohypoparathyroidism (PHP)	↓Ca, ↑PO₄, ↑PTH — looks biochemically like hypoparathyroidism but PTH is actually high (end-organ resistance to PTH). Phenotypic features: Albright hereditary osteodystrophy — short stature, round face, shortened 4th/5th metacarpals, mental retardation ^[8]. Cause: maternal GNAS1 mutation → defective Gsα → PTH receptor cannot signal	Genetic testing for GNAS1 mutation. Ellsworth-Howard test (infuse PTH → measure urinary cAMP and phosphate response — in PHP, no increase)
Chronic liver disease	Impaired 25-hydroxylation of vitamin D (first hydroxylation step occurs in liver). History of alcohol, viral hepatitis, etc.	LFT, 25-OH vitamin D (low), normal 1α-hydroxylase function (so 1,25-D₃ may be appropriate for the 25-OH-D level)
Medications	Loop diuretics (furosemide) → inhibit Na⁺/K⁺/2Cl⁻ cotransporter in thick ascending limb → abolish lumen-positive potential → ↓ paracellular Ca²⁺ reabsorption → hypocalciuria and hypocalcaemia ^[3]. Bisphosphonates → ↓ bone resorption → transient ↓Ca. Phenytoin/carbamazepine → induce CYP450 → accelerate vitamin D metabolism → ↓ vitamin D	Drug history!
Hungry bone syndrome (post-parathyroidectomy)	Acute profound hypocalcaemia after parathyroidectomy. Sudden drop in PTH → rapid deposition of calcium into demineralised bone that was previously being resorbed by excess PTH ^[2]	Timing: occurs post-operatively. ↓↓Ca, ↓PO₄, ↓Mg. PTH appropriately rising in response

Vitamin D Deficiency vs CKD as Causes of Secondary HPT — How to Tell Apart

The key distinguishing features:

Phosphate: In CKD, PO₄ is high (can't excrete it). In vitamin D deficiency with normal kidneys, PO₄ is low or normal (PTH drives phosphaturia and the kidneys comply).
25-OH vitamin D: Low in vitamin D deficiency. May also be low in CKD but is not the primary driver.
1,25-(OH)₂-D₃: Low in CKD (↓1α-hydroxylase). In pure vitamin D deficiency, the 1α-hydroxylase is intact, so 1,25-D₃ may be inappropriately normal or even high (driven by the elevated PTH stimulating the remaining substrate).
RFT: Abnormal in CKD, normal in vitamin D deficiency.

This is the critical differential because the management differs dramatically.

Differential	How to Distinguish	Key Investigations
Tertiary HPT	History of prolonged CKD/dialysis ± renal transplantation. Hypercalcaemia persists > 6–12 months post-transplant. All 4 glands typically enlarged	Clinical context is key. ↑Ca, ↑PTH, history of CKD. Imaging: USG + Sestamibi may show multigland enlargement
Primary HPT	No history of CKD. Sporadic or familial (MEN1, MEN2A). Usually single adenoma (85%) ^[2]^[3]. Can present at any age but peak in postmenopausal women	24h urine calcium (must check!) — will be high/normal in primary HPT ^[2]. Localisation: USG + Sestamibi scan ^[2]^[9]
Familial Hypocalciuric Hypercalcaemia (FHH)	Autosomal dominant. Inactivating mutation in CaSR → parathyroid gland "set point" for calcium is raised → mild hypercalcaemia with inappropriately normal or mildly elevated PTH. Crucially: 24h urine calcium is LOW (Ca/Cr clearance ratio < 0.01) because the renal CaSR is also affected → kidney reabsorbs too much calcium ^[2]^[5]. Lifelong, often asymptomatic, does NOT require surgery	24h urine Ca/Cr clearance ratio — this is the key test to differentiate FHH from primary HPT. FHH: < 0.01. Primary HPT: > 0.02. Grey zone: 0.01–0.02 (consider genetic testing)
Hypercalcaemia of malignancy	Usually PTH is suppressed (appropriately) because hypercalcaemia is PTH-independent. Mechanisms: ectopic PTHrP (SCC lung, HCC, breast), local osteolysis (breast, myeloma), ectopic 1,25-D₃ (lymphoma) ^[5]. Very rarely, ectopic PTH production can occur	PTH is low/suppressed (unlike tertiary HPT where PTH is high). PTHrP may be elevated. Cancer screen: CT CAP, serum/urine protein electrophoresis, tumour markers
Lithium use	Lithium shifts the CaSR set point → higher calcium required to suppress PTH → mild hypercalcaemia with inappropriately normal/elevated PTH. Can mimic primary HPT	Drug history! Lithium use in psychiatric patients (bipolar disorder). Resolves on cessation (though some develop true adenoma with prolonged use)

Exam pearl: The single most important investigation to distinguish primary HPT from FHH is the 24h urine calcium ^[2]. FHH is a benign condition that does NOT require parathyroidectomy — operating on an FHH patient is a classic exam pitfall.

Common Exam Mistake

Students often confuse tertiary HPT with primary HPT because both present with ↑Ca and ↑PTH. The distinction is entirely clinical context:

Primary HPT: No prior renal disease. Sporadic adenoma or MEN-associated.
Tertiary HPT: Always has a background of prolonged secondary HPT (CKD/dialysis). Usually post-transplant.

Biochemically they can look identical — the history is what separates them. Also, in primary HPT you expect a single adenoma in ~85% of cases, whereas in tertiary HPT, all 4 glands are typically enlarged (diffuse/nodular hyperplasia with autonomous transformation).

When managing a CKD patient with hypocalcaemia, don't automatically assume it's all secondary HPT — there may be additional contributing factors:

Differential	Distinguishing Features
Hypomagnesaemia	Severe hypoMg (< 0.3 mmol/L) → inhibits both PTH secretion and PTH action → hypocalcaemia refractory to calcium replacement ^[8]. Classic triad: hypoCa + hypoK + hypoMg. Common in CKD patients on loop diuretics, proton pump inhibitors, or with GI losses
Aluminium toxicity	Historical cause — aluminium-containing phosphate binders (now rarely used). Aluminium deposits in bone → impairs mineralisation → osteomalacia variant. Also deposits at the mineralisation front → adynamic bone disease. Diagnosed by aluminium levels, desferrioxamine test
Adynamic bone disease (iatrogenic over-suppression of PTH)	Over-treatment with vitamin D analogues or calcimimetics → excessive PTH suppression → too little bone turnover → hypocalcaemia can paradoxically occur because the bone can't buffer calcium normally ^[4]. PTH is inappropriately low for a CKD patient
Post-parathyroidectomy hypoparathyroidism	If the patient has had prior parathyroid surgery → permanent hypoparathyroidism → ↓PTH → ↓Ca ^[2]
Acute pancreatitis	Saponification of calcium in necrotic fat → acute drop in ionised Ca²⁺
Massive transfusion / citrate toxicity	Citrate in stored blood chelates ionised calcium → acute hypocalcaemia

Differential	How to Distinguish
Osteoporosis (age-related, post-menopausal, steroid-induced)	DEXA scan shows ↓BMD. Normal Ca/PO₄/PTH. CKD patients on long-term steroids post-transplant are at high risk
Myeloma bone disease	Lytic lesions (not blastic), anaemia, renal impairment, hypercalcaemia with suppressed PTH, ↑globulin, Bence Jones proteinuria. Serum/urine protein electrophoresis, bone marrow biopsy
Paget's disease of bone	Localised (not generalised). Markedly elevated ALP with normal Ca and PO₄ (unless immobilised → then ↑Ca). Characteristic radiological features: cortical thickening, mixed lytic/sclerotic lesions, bowing of long bones ^[3]. Can coexist with CKD-MBD
Metastatic bone disease	History of primary malignancy (breast, prostate, lung, kidney, thyroid). Focal bone pain, pathological fractures. Bone scan shows focal uptake (vs. superscan in secondary HPT which is diffuse symmetric) ^[9]
Myelofibrosis	Bone marrow fibrosis — can be associated with secondary HPT as a non-haematological cause of marrow fibrosis ^[10]. Distinguished by blood film (tear-drop cells, leucoerythroblastic picture), splenomegaly, and bone marrow biopsy

Feature	Secondary HPT	Tertiary HPT	Primary HPT	FHH
Serum Ca²⁺	↓ or normal	↑	↑	Mild ↑
Serum PO₄	↑ (CKD)	Variable	↓ or normal	Normal
PTH	↑ (appropriate)	↑ (inappropriate)	↑ (inappropriate)	Normal or mild ↑
25-OH Vit D	Often ↓	Variable	Check to rule out deficiency	Normal
1,25-(OH)₂-D₃	↓	May normalise post-Tx	↑ (PTH stimulates 1α-hydroxylase)	Normal
24h urine Ca	↓ (CKD)	Variable	↑	↓↓ (< 0.01 Ca/Cr ratio)
RFT	Abnormal	Often abnormal (prior CKD)	Normal	Normal
Gland pathology	4-gland hyperplasia	Nodular hyperplasia / adenomatous	Single adenoma (85%)	Normal glands
CKD/dialysis Hx	Yes	Yes	No	No
Surgery needed?	Rarely (medical Mx first)	Often yes	Often yes	No

High Yield Summary — Differential Diagnosis

When you see ↑PTH, always ask: What is the calcium?

↑PTH + ↓/normal Ca → Secondary HPT (CKD > vitamin D deficiency > calcium malabsorption > pseudohypoparathyroidism > medications)
↑PTH + ↑Ca → Tertiary HPT (if CKD/transplant background), Primary HPT (if no renal history), or FHH (if low urine calcium)
↓PTH + ↑Ca → NOT hyperparathyroidism at all — think malignancy, vitamin D intoxication, granulomatous disease, thiazide diuretics

Key distinguishing tests:

RFT and eGFR — separates CKD-related causes from non-CKD
25-OH Vitamin D — identifies vitamin D deficiency
24h urine calcium — separates primary HPT from FHH (must check!) ^[2]
Serum phosphate — high in CKD, low/normal in primary HPT and vitamin D deficiency
Clinical context — history of CKD, dialysis, transplantation is what separates secondary/tertiary HPT from primary HPT

Don't forget: Pseudohypoparathyroidism (PTH resistance — GNAS1 mutation) mimics hypoparathyroidism biochemically but has HIGH PTH. Distinguished by Albright hereditary osteodystrophy phenotype and genetic testing ^[8].

Active Recall - Differential Diagnosis of Secondary & Tertiary HPT

References

^[2] Senior notes: maxim.md (Primary hyperparathyroidism, Tertiary hyperparathyroidism sections) ^[3] Senior notes: Ryan Ho Endocrine.pdf (p41 — Hyperparathyroidism classification; p53 — Paget's disease) ^[4] Senior notes: Ryan Ho Urogenital.pdf (p107 — CKD-MBD, adynamic bone disease, iatrogenic contributions) ^[5] Senior notes: Ryan Ho Fundamentals.pdf (p430 — Hypercalcemia approach, PTH-dependent vs independent) ^[8] Senior notes: Ryan Ho Chemical Path.pdf (p25 — Pseudohypoparathyroidism, hypomagnesaemia, renal failure hypocalcaemia) ^[9] Senior notes: Ryan Ho Diagnostic Radiology.pdf (p60 — Parathyroid scintigraphy; p68 — Bone scan, superscan) ^[10] Senior notes: Ryan Ho Haemtology.pdf (p77 — Myelofibrosis, secondary HPT as associated condition)

Diagnostic Criteria, Algorithm & Investigations for Secondary & Tertiary HPT

Diagnosis	Biochemical Pattern	Clinical Context Required
Secondary HPT	↑PTH + ↓ or normal Ca²⁺ + usually ↑PO₄ (if CKD) or ↓PO₄ (if vit D deficiency)	Known CKD (most common), vitamin D deficiency, calcium malabsorption, or other cause of chronic hypocalcaemia
Tertiary HPT	↑PTH + ↑Ca²⁺ (hypercalcaemia)	History of prolonged secondary HPT (CKD/dialysis), typically diagnosed > 6–12 months post-renal transplant when hypercalcaemia persists despite restoration of renal function ^[2]^[4]

When Exactly Does Secondary Become Tertiary?

There is no single PTH cutoff that defines the transition. The key distinction is autonomy: if you remove the stimulus (e.g., by transplanting a kidney) and the PTH still doesn't come down and the patient is hypercalcaemic, the glands have become autonomous = tertiary HPT. Practically, most clinicians allow 6–12 months post-transplant for regression before labelling it tertiary. On dialysis without transplant, "tertiary" is diagnosed when the patient develops persistent hypercalcaemia despite optimal medical management of secondary HPT.

While not "diagnostic criteria," the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines provide target ranges for biochemical markers in CKD-MBD that define when secondary HPT is clinically significant and needs treatment:

Parameter	CKD Stage 3–5 (not on dialysis)	CKD Stage 5D (on dialysis)
PTH	Maintain within normal range for the assay	Maintain at 2–9× the upper limit of normal for the assay (typically ~130–600 pg/mL for intact PTH assays with ULN ~65 pg/mL)
Serum Calcium	Maintain within normal range	Maintain within normal range
Serum Phosphate	Maintain within normal range	Lower towards normal range (target ~1.13–1.78 mmol/L)
ALP	Monitor trends	Monitor trends — persistent elevation suggests high turnover bone disease

Why is the PTH target so high in dialysis patients (2–9× ULN)? Because some degree of elevated PTH is actually needed to maintain adequate bone turnover. Suppressing PTH too aggressively leads to adynamic bone disease (low turnover → brittle bone → fractures, and inability to buffer calcium → hypercalcaemia episodes) ^[4]. The PTH target intentionally accepts mild hyperparathyroidism to avoid over-suppression.

Exam Pearl

A common mistake is treating PTH to normal levels in a dialysis patient. You should NOT aim for normal PTH in dialysis patients — the target is 2–9× ULN. Over-suppression causes adynamic bone disease, which is increasingly the most common form of renal osteodystrophy ^[4].

Investigation Modalities: Detailed Breakdown

These are done in every patient with suspected or confirmed secondary/tertiary HPT.

Investigation	What It Tells You	Key Findings & Interpretation
Serum Calcium (total + albumin-corrected, or ionised)	The central parameter — determines whether HPT is secondary (↓/normal Ca) or tertiary (↑Ca)	Corrected Ca = total Ca + 0.02 × (40 – albumin in g/L). In CKD, hypoalbuminaemia is common → total Ca may be falsely low → always correct for albumin or use ionised calcium (gold standard). Ionised Ca is also affected by acid-base status: acidosis → ↑ ionised Ca (H⁺ displaces Ca²⁺ from albumin), alkalosis → ↓ ionised Ca
Serum Phosphate	Reflects GFR and dietary phosphate load	↑ in CKD (can't excrete). ↓ or normal in vitamin D deficiency (PTH-driven phosphaturia works because kidneys are functioning). ↑PO₄ is a key driver of the entire CKD-MBD cascade and a treatment target
Intact PTH (iPTH)	Confirms hyperparathyroidism and guides treatment	Measured by 2nd-generation immunometric assays (detect 1–84 PTH). Normal range varies by assay (~10–65 pg/mL). In CKD 5D, target 2–9× ULN (~130–600 pg/mL). Note: PTH should be interpreted in context — an "in-range" PTH may be inappropriately normal if Ca is high (suggesting autonomy in tertiary HPT) ^[5]
25-OH Vitamin D	Reflects vitamin D stores (intake + cutaneous production)	Must check in all patients ^[3]. Low 25-OH-D (< 75 nmol/L insufficient, < 50 nmol/L deficient) → contributing to secondary HPT. Should be repleted before assuming secondary HPT is purely renal. KDIGO recommends correcting vitamin D deficiency in CKD patients as a first-line measure
1,25-(OH)₂-D₃ (calcitriol)	Reflects active vitamin D (produced by renal 1α-hydroxylase)	↓ in CKD (↓ renal mass → ↓ 1α-hydroxylase). Not routinely measured in CKD (because it's expected to be low). More useful for distinguishing vitamin D-dependent rickets type I (low) from type II (high/normal) ^[8]^[11]
Serum ALP (total and bone-specific)	Marker of bone turnover (osteoblastic activity)	↑ ALP = high bone turnover (osteitis fibrosa cystica). Trends in ALP are more useful than single values. ↑ ALP predicts risk of hungry bone syndrome post-operatively ^[2] — because it indicates highly active bone that will "soak up" calcium rapidly when PTH drops after surgery. Bone-specific ALP is more specific than total ALP (which can also rise in liver disease)
RFT (urea, creatinine, eGFR, electrolytes)	Confirms CKD and stages severity	eGFR determines CKD stage and guides treatment targets. Also check potassium (CKD → hyperkalaemia), bicarbonate (metabolic acidosis of CKD contributes to bone buffering → worsens bone disease)
Serum Magnesium	Rule out hypomagnesaemia as contributor	Severe hypoMg (< 0.3 mmol/L) → inhibits PTH secretion and action → hypocalcaemia refractory to calcium replacement ^[5]^[8]. Classic triad: hypoCa + hypoK + hypoMg. Must check in any refractory case
Serum Albumin	Needed for calcium correction	Hypoalbuminaemia (common in CKD — nephrotic syndrome, malnutrition, chronic inflammation) → ↓ total Ca but ionised Ca may be normal

Investigation	When to Order	Key Findings & Interpretation
24-hour urine calcium	Must check when hypercalcaemia + ↑PTH to rule out FHH ^[2]^[3] — essential in tertiary HPT to differentiate from FHH. Also done in primary HPT workup. Less useful in dialysis patients (anuric or oliguric)	FHH: Ca/Cr clearance ratio < 0.01. Primary/Tertiary HPT: > 0.02. Grey zone 0.01–0.02 → genetic testing. Formula: (urine Ca × serum Cr) / (serum Ca × urine Cr)
FGF-23	Research interest / specialised centres. Earliest marker of CKD-MBD — rises before PTH or PO₄	↑ in CKD from early stages. Not yet routinely measured in clinical practice (no established treatment target). May become more important as targeted therapies develop
Aluminium level	If suspicion of aluminium toxicity (increasingly rare) — patients on aluminium-containing phosphate binders or using aluminium-contaminated dialysate	↑ serum aluminium → consider desferrioxamine (DFO) test. Aluminium deposits in bone → osteomalacia/adynamic bone disease variant

Investigation	Purpose	Key Findings
Plain XR hands (AP)	Screen for subperiosteal resorption — the pathognomonic radiological sign of hyperPTH	Look at the radial side of the middle phalanges — earliest and most sensitive site. Cortex appears "moth-eaten" or eroded. Also check for tuft resorption (acro-osteolysis) of distal phalanges
Plain XR pelvis / spine	Assess for bone disease and fractures	Rugger jersey spine: alternating sclerotic endplates and lucent vertebral body centres (sclerosis from new bone formation at endplates where stress is maximal, lucency from resorption centrally). Brown tumours: well-defined lytic lesions. Vertebral compression fractures. Looser zones (osteomalacia)
Skull XR	Classical but less commonly done now	Salt and pepper skull: diffuse granular mottling from trabecular bone resorption throughout the calvarium ^[3]
KUB / USG kidneys	Screen for nephrolithiasis and nephrocalcinosis	Calcium-containing stones (calcium oxalate, calcium phosphate). Nephrocalcinosis: diffuse medullary calcification from chronic hypercalciuria ^[1]
DEXA scan	Assess bone mineral density	KDIGO recommends DEXA in CKD Stage 3–5D if results will influence treatment. In hyperPTH: cortical bone (1/3 radius, hip) more affected than trabecular (spine) because PTH preferentially resorbs cortical bone ^[3]. Note: DEXA can underestimate fracture risk in CKD because it doesn't distinguish between bone quality issues
Lateral spine XR or VFA	Screen for vertebral fractures	Vertebral fracture assessment (VFA) on DEXA or lateral spine XR — many vertebral fractures are asymptomatic ("morphometric fractures")
ECG	Screen for cardiac effects of calcium disturbance	Hypocalcaemia: prolonged QT interval → risk of arrhythmia. Hypercalcaemia (tertiary HPT): shortened QT interval, possible Osborn (J) waves in severe cases
Echocardiogram	Assess for cardiac calcification and LVH	Valve calcification (aortic, mitral), LVH (from hypertension and uraemia), pericardial effusion. Vascular calcification is a major component of CKD-MBD
CT coronary calcium score / plain lateral abdominal XR	Screen for vascular calcification	KDIGO suggests using lateral abdominal XR or echocardiography as alternatives to CT for detecting vascular calcification. Presence of vascular calcification should influence choice of phosphate binder (avoid calcium-based binders) ^[4]

Critical Concept

Localisation studies are NOT for diagnosis of hyperparathyroidism ^[1]^[9]. They are performed only after the biochemical diagnosis is confirmed and a decision for surgery has been made. Their role is to guide the surgical approach (minimally invasive vs bilateral exploration). A negative localisation study does not exclude the diagnosis and does not preclude surgery.

Modality	Mechanism & Technique	Key Findings	Limitations
USG neck	Non-invasive, real-time imaging. Parathyroid adenomas/hyperplastic glands appear as hypoechoic, well-defined, ovoid masses posterior to the thyroid, often with a feeding vessel on Doppler ^[1]^[2]	Enlarged parathyroid gland(s). In tertiary HPT, typically all 4 glands enlarged (vs. single adenoma in primary HPT). Can also detect concomitant thyroid nodules	Operator-dependent. Poor for ectopic glands (mediastinal, retroesophageal). Cannot detect glands behind air-filled trachea or oesophagus. Sensitivity ~70–80% for single adenomas, lower for multigland disease
99mTc-Sestamibi scan (parathyroid scintigraphy) ^[2]^[9]	Sestamibi accumulates in mitochondria — parathyroid tissue is rich in oxyphilic cells (lots of mitochondria) → slow washout compared to thyroid tissue. Dual-phase technique: early image (10–20 min) shows uptake in both thyroid and parathyroid → delayed image (2 hours) shows washout from thyroid but retained activity in parathyroid ^[2]^[9]	Focal retained activity on delayed imaging = hyperfunctioning parathyroid tissue. In tertiary HPT, may show multiple foci of retention (multigland disease)	False positive: Hurthle cell adenoma of thyroid (also mitochondria-rich) ^[2]. False negative: common in multigland hyperplasia (sensitivity lower than for single adenomas — ~50–60% for multigland vs ~85–90% for single adenoma), small glands, concurrent thyroid disease. Sensitivity is lower in secondary/tertiary HPT than in primary HPT because the disease is multigland
SPECT/CT (single-photon emission CT)	Fuses Sestamibi scintigraphy with CT → 3D anatomical localisation	Higher resolution than planar Sestamibi. Better for ectopic glands (mediastinal, intrathyroidal) ^[2]	Radiation dose. Still limited sensitivity in multigland disease
4D-CT scan	Multiphase CT imaging (non-contrast, arterial, delayed phases). Parathyroid adenomas enhance avidly in arterial phase and wash out on delayed phase (4th dimension = time)	Very high spatial resolution. Increasingly used when Sestamibi/USG are discordant or negative	High radiation dose ^[2]. Less widely available. Better for re-operative cases
MRI neck	Parathyroid tissue shows low signal on T1, high signal on T2 ^[1]. Useful for mediastinal ectopic glands	Alternative when radiation is a concern. Good for mediastinal assessment	Lower sensitivity than Sestamibi for typical neck glands
PET/CT (11C-methionine or 18F-fluorocholine)	Newer tracer — amino acid analogue taken up by metabolically active parathyroid cells. 18F-fluorocholine PET/CT is emerging as superior to Sestamibi in some studies	Higher sensitivity than Sestamibi, especially for multigland disease and small glands. Increasingly used in tertiary HPT where Sestamibi sensitivity is limited	Limited availability, cost, not yet standard of care everywhere
Parathyroid angiography with selective venous sampling	Invasive, reserved for re-operative cases or when non-invasive imaging is unrevealing ^[2]. Selective catheterisation of cervical veins → PTH sampling from different venous drainage territories. A 1.5–2× increase in PTH from a specific cervical vein compared to peripheral suggests ipsilateral hyperfunctioning gland ^[1]	Lateralises the hyperfunctioning tissue. Can also combine with selective arterial stimulation (inject sodium citrate to induce local hypocalcaemia → stimulate PTH release from abnormal gland)	Invasive, requires experienced interventional radiologist. Reserved for failed first surgery or discordant non-invasive imaging

Practical point for tertiary HPT: Because tertiary HPT is almost always multigland disease (all 4 glands enlarged), localisation is less about finding a single culprit and more about (a) confirming all glands are enlarged, (b) excluding ectopic/supernumerary glands, and (c) planning the surgical approach (bilateral neck exploration is usually required, not focused parathyroidectomy).

Investigation	When Used	Interpretation
Intraoperative PTH (ioPTH) monitoring	During parathyroidectomy for tertiary HPT — blood samples taken before resection and at defined intervals post-resection (typically 5, 10, 15 min)	Miami criteria: PTH should drop to normal range + < 50% of the highest pre-incision or pre-excision value at 10 minutes post-resection ^[2]. If criteria not met → suspect residual hyperfunctioning tissue → extend exploration. Note: In subtotal parathyroidectomy for tertiary HPT, the remnant will still produce some PTH, so ioPTH interpretation is modified
Frozen section	During subtotal parathyroidectomy — the resected half of the "remnant" gland is sent for frozen section ^[2]	Confirms the tissue is parathyroid (not fat, thyroid, lymph node). Essential to ensure the remnant left in situ is actually parathyroid tissue

Investigation	When to Consider	What It Shows
Transiliac bone biopsy (after double tetracycline labelling)	When clinical and biochemical data are discordant (e.g., fractures despite seemingly adequate PTH levels), suspected aluminium toxicity, unexplained hypercalcaemia in dialysis, before starting anti-resorptive therapy in CKD	TMV classification: Turnover (high/low), Mineralisation (normal/abnormal), Volume (high/low). Distinguishes: osteitis fibrosa cystica (high turnover), osteomalacia (low turnover, abnormal mineralisation), adynamic bone disease (low turnover, normal mineralisation), mixed uraemic osteodystrophy ^[4]

This integrates all the biochemical patterns for quick reference and examination recall ^[1]^[3]^[5]:

Condition	Ca²⁺	PO₄	PTH	25-OH-D	1,25-(OH)₂-D	ALP	24h Urine Ca
Secondary HPT (CKD)	↓/N	↑	↑	Often ↓	↓	↑	↓ (anuric)
Secondary HPT (Vit D deficiency)	↓/N	↓/N	↑	↓↓	Variable	↑	↓
Tertiary HPT	↑	↑ or N	↑	Variable	May normalise	↑	Variable
Primary HPT	↑	↓/N	↑	Check	↑	↑ if bone disease	↑/N
FHH	Mild ↑	N	N/mild ↑	N	N	N	↓↓
Malignancy (PTHrP)	↑	↓/N	↓	N	N	↑ if bone mets	↑
Malignancy (bone mets)	↑	↑/N	↓	N	N	↑	↑
Vit D intoxication	↑	↑	↓	↑↑	↑	N	↑
Granulomatous disease	↑	N	↓	N	↑↑	N	↑

Step 1: Confirm the biochemistry — Ca (corrected or ionised), PO₄, PTH, 25-OH vitamin D, ALP, RFT, Mg²⁺

Step 2: Classify the HPT

↑PTH + ↓/N Ca → Secondary HPT → Determine cause (CKD vs vitamin D deficiency vs other)
↑PTH + ↑Ca + CKD/transplant history → Tertiary HPT → Check 24h urine Ca to rule out FHH

Step 3: Assess severity and screen for complications

Bone: XR hands, spine, pelvis; DEXA; lateral spine XR
Renal: KUB / USG kidneys (stones, nephrocalcinosis)
Cardiovascular: ECG, echo, vascular calcification screening
Bloods: FBC (anaemia), lipids (CV risk)

Step 4: Pre-operative localisation (if surgery planned)

USG neck + Sestamibi scan ^[2]^[9] as first-line
SPECT/CT or 4D-CT if discordant or negative
Selective venous sampling reserved for re-operative cases ^[2]

Step 5: Intraoperative confirmation

ioPTH monitoring (Miami criteria) ^[2]
Frozen section of remnant tissue ^[2]

High Yield Summary — Diagnosis of Secondary & Tertiary HPT

No formal diagnostic criteria exist — diagnosis is biochemistry + clinical context.
Secondary HPT: ↑PTH + ↓/N Ca + known cause of chronic hypocalcaemia (CKD, vitamin D deficiency).
Tertiary HPT: ↑PTH + ↑Ca persisting > 6–12 months post-transplant (or on dialysis with hypercalcaemia despite medical Mx).
KDIGO targets for CKD 5D: PTH 2–9× ULN. Do NOT suppress PTH to normal → adynamic bone disease ^[4].
Must-check investigations: RFT, Ca (corrected), PO₄, PTH, 25-OH-D, ALP, Mg²⁺. In hypercalcaemia: 24h urine Ca to rule out FHH ^[2].
Localisation studies (USG + Sestamibi) are NOT diagnostic — only for surgical planning after biochemical confirmation ^[1]^[9].
Sestamibi mechanism: accumulates in mitochondria-rich oxyphilic cells → slow washout from parathyroid vs thyroid on dual-phase imaging ^[2]^[9]. False positive: Hurthle cell adenoma. Lower sensitivity in multigland disease (i.e., secondary/tertiary HPT).
ioPTH monitoring: Miami criteria — PTH drops to normal range + < 50% of max value at 10 min post-excision ^[2].
Bone biopsy (transiliac, double tetracycline labelling) = gold standard for classifying renal osteodystrophy (TMV system) but rarely needed in practice ^[4].

Active Recall - Diagnosis of Secondary & Tertiary HPT

References

^[1] Senior notes: felixlai.md (Localisation studies, biochemical tests, case study) ^[2] Senior notes: maxim.md (Primary hyperparathyroidism investigations, Sestamibi mechanism, Miami criteria, surgical options) ^[3] Senior notes: Ryan Ho Endocrine.pdf (p42 — Diagnosis, standard Ix, D/dx of primary HPT) ^[4] Senior notes: Ryan Ho Urogenital.pdf (p107 — CKD-MBD pathogenesis, iatrogenic contributions, adynamic bone disease) ^[5] Senior notes: Ryan Ho Fundamentals.pdf (p430–432 — Hypercalcemia approach, hypocalcaemia management, vitamin D failure) ^[8] Senior notes: Ryan Ho Chemical Path.pdf (p25–26 — Renal failure hypocalcaemia, vitamin D metabolism, pseudohypoparathyroidism) ^[9] Senior notes: Ryan Ho Diagnostic Radiology.pdf (p60 — Parathyroid scintigraphy, localisation role; p68 — Bone scan) ^[11] Senior notes: Ryan Ho Chemical Path.pdf (p26 — Vitamin D metabolism investigations)

Management of Secondary & Tertiary Hyperparathyroidism

The management of secondary and tertiary HPT is fundamentally different because the underlying problem is different:

Secondary HPT: The glands are doing their job — the problem is the environment (CKD, vitamin D deficiency). Fix the environment → glands settle down. Management is overwhelmingly medical.
Tertiary HPT: The glands have become autonomous — the environment has been fixed (e.g., transplant) but the glands won't stop. Management is often surgical.

Let's build this systematically.

PART 1: Management of Secondary HPT

The principle is simple: remove the stimulus driving PTH secretion. In CKD, that means correcting hyperphosphataemia, hypocalcaemia, and vitamin D deficiency.

A. Phosphate Control — The Foundation of Treatment

Why start here? Because hyperphosphataemia is the initial trigger of the entire CKD-MBD cascade ^[4]. If you don't control phosphate, nothing else will work properly.

Aspect	Details
Target	Serum PO₄ towards normal range (KDIGO: lower towards normal in CKD 3–5; ~1.13–1.78 mmol/L in CKD 5D)
Approach	Restrict dietary phosphate to 800–1000 mg/day. Focus on reducing processed foods, preserved meats, cola drinks (phosphoric acid), dairy products. In Hong Kong, common high-phosphate foods include preserved eggs (皮蛋), organ meats, dried seafood, instant noodles
Rationale	Phosphate is ubiquitous in food — restriction alone is usually insufficient (dialysis only clears ~300 mg PO₄ per session, while dietary intake can be 1000–1500 mg/day). Hence binders are almost always needed
Limitation	Overly strict restriction risks protein-energy malnutrition (phosphate correlates with protein intake) — must balance phosphate restriction with adequate protein nutrition, especially in dialysis patients

These are taken with meals to bind dietary phosphate in the gut and prevent absorption. Think of them as "phosphate sponges."

Binder	Mechanism	Advantages	Disadvantages
Calcium carbonate	Ca²⁺ binds PO₄ in gut → insoluble CaPO₄ → excreted in stool	Cheap, widely available, also provides calcium supplementation	Net positive calcium balance → risk of hypercalcaemia and vascular calcification ^[4]. KDIGO recommends restricting calcium-based binders in patients with vascular calcification, adynamic bone disease, or persistent hypercalcaemia
Calcium acetate	Same as above but binds more PO₄ per unit of calcium absorbed	More efficient phosphate binding per calcium load	Same risks as calcium carbonate but slightly less calcium absorption per tablet
Sevelamer ("sevel" = "sever" the link between phosphate and absorption)	Non-calcium, non-aluminium polymer that binds PO₄ in gut via ion exchange	No calcium load → avoids vascular calcification. Also ↓LDL cholesterol (a bonus in CKD patients with high CV risk). May reduce FGF-23 levels	Expensive. Large pill burden (multiple large tablets with each meal). Can cause GI side effects (nausea, bloating)
Lanthanum carbonate	Lanthanum (a rare earth metal) binds PO₄ in gut	Potent PO₄ binding. Low systemic absorption. Non-calcium	Expensive. Theoretical concern about lanthanum accumulation (though clinical significance uncertain). Chewable tablets
Sucroferric oxyhydroxide	Iron-based PO₄ binder	Lower pill burden than sevelamer. Non-calcium	Dark stools (iron). GI side effects
Aluminium hydroxide	Aluminium binds PO₄ very effectively	Very effective	Largely abandoned due to aluminium toxicity — accumulates in bone (osteomalacia), brain (dialysis dementia/encephalopathy), and marrow (microcytic anaemia). Only used short-term for severe refractory hyperphosphataemia ^[4]

Choosing a Phosphate Binder — The Key Decision

The main clinical decision is calcium-based vs non-calcium-based binders. KDIGO 2017 suggests restricting the dose of calcium-based phosphate binders in all CKD patients, and avoiding them entirely in patients with: (1) vascular/soft tissue calcification, (2) adynamic bone disease (low PTH — can't deposit calcium into bone), (3) persistent hypercalcaemia. In these patients, use sevelamer or lanthanum instead ^[4].

B. Vitamin D Therapy

This operates on two levels: correcting nutritional vitamin D deficiency and providing active vitamin D analogues to directly suppress PTH.

Aspect	Details
Goal	Correct 25-OH vitamin D to > 75 nmol/L (30 ng/mL)
Rationale	Vitamin D deficiency is extremely common in CKD patients AND contributes independently to secondary HPT. KDIGO recommends correcting vitamin D deficiency/insufficiency before starting active vitamin D analogues
Agents	Cholecalciferol (D₃ — from animal/sunlight) or Ergocalciferol (D₂ — from plants). D₃ is generally preferred (longer half-life, more potent)
Limitation	In advanced CKD (Stage 4–5), even repleted 25-OH-D cannot be activated because 1α-hydroxylase activity is severely reduced → need active analogues

Agent	Mechanism	Indications	Key Side Effects
Calcitriol (1,25-(OH)₂-D₃)	The active form of vitamin D — bypasses the need for renal 1α-hydroxylation. Directly: (a) ↑ intestinal Ca absorption, (b) suppresses PTH gene transcription via VDR on parathyroid cells, (c) ↑ CaSR expression on parathyroid glands	Secondary HPT in CKD 3–5D when PTH is progressively rising above target despite phosphate control and nutritional vitamin D repletion	Hypercalcaemia and hyperphosphataemia (increases gut absorption of both Ca and PO₄). Must monitor Ca and PO₄ closely. Can cause adynamic bone disease if PTH is over-suppressed ^[4]
Alfacalcidol (1α-OH-D₃)	Requires only 25-hydroxylation in liver (not renal 1α-hydroxylation) → effectively an active vitamin D analogue. Widely used in Hong Kong	Same as calcitriol	Same as calcitriol. Slightly longer half-life
Paricalcitol	Selective VDR activator — activates VDR in parathyroid gland (suppresses PTH) but has less effect on gut calcium/phosphate absorption	Secondary HPT when calcitriol/alfacalcidol cause hypercalcaemia or hyperphosphataemia. Theoretically "safer" profile	Still can cause hypercalcaemia (though less than calcitriol). Expensive
Doxercalciferol	Pro-drug, activated by hepatic 25-hydroxylase	Alternative to paricalcitol	Similar to paricalcitol

Why does vitamin D suppress PTH? Calcitriol binds to the Vitamin D Receptor (VDR) in parathyroid chief cells → the VDR-calcitriol complex binds to negative regulatory elements on the PTH gene promoter → directly suppresses PTH mRNA transcription. It also upregulates CaSR expression → makes the gland more sensitive to calcium → less PTH secretion. This dual mechanism makes vitamin D a potent PTH suppressor ^[4].

The Over-Suppression Trap

Over-treatment with active vitamin D analogues is one of the most common iatrogenic problems in CKD-MBD management. If you suppress PTH too much (below 2× ULN in dialysis patients), you push the patient into adynamic bone disease — the bone can't remodel, becomes brittle, fractures occur, and the bone can't buffer calcium → episodes of hypercalcaemia. Always monitor PTH trends and avoid driving it to normal ^[4].

Calcimimetics — "calci" = calcium, "mimetic" = mimicking. These drugs mimic the action of calcium on the CaSR.

Agent	Mechanism	Indications	Key Details
Cinacalcet (oral)	Allosteric activator of the CaSR on parathyroid chief cells → makes the receptor "think" calcium is higher than it actually is → ↓ PTH secretion. Also ↓ parathyroid cell proliferation over time ^[1]^[2]^[3]	Secondary HPT in CKD 5D (on dialysis) refractory to phosphate binders and vitamin D analogues. Also used in tertiary HPT when surgery is contraindicated or patient is unfit ^[2]. Also used in primary HPT when parathyroidectomy is indicated but contraindicated ^[1]^[3]	Dose: start 30 mg daily, titrate up (max 180 mg/day). Side effects: nausea, vomiting (very common — up to 30%), hypocalcaemia (must monitor Ca closely), QT prolongation. Contraindication: hypocalcaemia (will worsen it)
Etelcalcetide (IV)	Same mechanism as cinacalcet but given IV at the end of dialysis sessions	Secondary HPT in CKD 5D, especially for patients who cannot tolerate oral cinacalcet (GI side effects) or have compliance issues	Avoids GI side effects. Must be given thrice weekly with dialysis. Can cause hypocalcaemia

Cinacalcet is effective in lowering/normalising serum calcium but has less consistent effect on serum PTH and no consistent effect on BMD ^[3]. This is an important nuance — it controls hypercalcaemia well but doesn't necessarily fix the bone disease.

Strategy	Rationale
Adequate dialysis clearance (Kt/V > 1.2 for HD)	Better phosphate and uraemic toxin clearance → less stimulus for PTH
Dialysate calcium concentration	Typically 1.25–1.5 mmol/L. Higher dialysate Ca → suppresses PTH during dialysis but risk of positive Ca balance and vascular calcification. Lower dialysate Ca → may worsen secondary HPT. Must individualise
Longer/more frequent dialysis sessions	Nocturnal HD or daily HD improves phosphate clearance significantly (conventional thrice-weekly HD only removes ~300 mg PO₄/session, while intake can be ~1000 mg/day)

Measure	Rationale
Correct metabolic acidosis (oral sodium bicarbonate)	Chronic metabolic acidosis in CKD → bone acts as a buffer → releases calcium carbonate from bone → worsens bone loss. Correcting acidosis ↓ bone buffering need
Avoid excessive calcium supplementation	Net positive calcium balance → vascular calcification. KDIGO recommends total elemental calcium intake (diet + binders + supplements) should not exceed ~1500–2000 mg/day
Treat anaemia (ESA, iron)	Anaemia worsens fatigue and bone marrow function. Not directly related to PTH but part of holistic CKD management

PART 2: Management of Tertiary HPT

Tertiary HPT is a surgical disease in most cases, because the fundamental problem is autonomous gland tissue that will not respond to medical manipulation.

B. Surgical Options for Tertiary HPT

Because tertiary HPT is multigland disease (all 4 glands are hyperplastic/autonomous), focused parathyroidectomy is NOT appropriate — you must address all glands. The options are:

Procedure	Description	When to Choose	Advantages	Disadvantages
Subtotal parathyroidectomy ("three-and-a-half resection") ^[2]	3 glands completely resected + half of the 4th (most normal-appearing) gland resected (sent for frozen section to confirm parathyroid tissue). The remaining half gland is left in situ, marked with non-absorbable sutures for identification if re-operation needed ^[2]	Most common approach for tertiary HPT, especially in transplant patients	Preserves some parathyroid function → lower risk of permanent hypoparathyroidism. Allows some PTH production to maintain bone health	Risk of recurrence (the remnant can re-hypertrophy). If recurrence occurs, re-operative neck surgery is needed (more difficult)
Total parathyroidectomy with autotransplantation ^[2]	All 4 glands completely resected. Small fragments of the most normal-appearing gland are implanted into a muscle pocket — typically the forearm (brachioradialis) or neck (SCM) ^[2]	Preferred when recurrence risk is high or when easy access for future surgery is desired	If the autograft hypertrophies and causes recurrence, it can be excised under local anaesthesia from the forearm (much easier than re-operating on the neck). Complete removal of all neck parathyroid tissue	Risk of permanent hypoparathyroidism if autograft fails to function. Period of hypoparathyroidism while graft takes (typically days to weeks — patient needs calcium + vitamin D supplementation)
Total parathyroidectomy (without autotransplantation)	All 4 glands resected, no graft	Only considered when renal transplant is highly unlikely (i.e., patient will remain on dialysis indefinitely and will never have functional kidneys) ^[2]	Eliminates all autonomous tissue → no recurrence possible	Results in permanent hypoparathyroidism → lifelong calcium and vitamin D supplementation. Acceptable if patient is on dialysis (where calcium is managed via dialysate) but not acceptable if transplant is planned

Why Autotransplant to the Forearm?

The forearm (brachioradialis) is chosen because: (1) it is a superficial, easily accessible site — if the graft hypertrophies and causes recurrent HPT, it can be excised under local anaesthesia in clinic without a neck re-operation; (2) adequate blood supply for graft survival; (3) graft function can be confirmed by sampling PTH from the antecubital veins on that arm (gradient between grafted and non-grafted arm). The neck (SCM) is an alternative site. Graft tissue is typically implanted as small fragments (1 mm pieces) into muscle pockets ^[2].

Aspect	Details
Incision	Kocher's incision (transverse collar incision) — same as for thyroidectomy. Bilateral neck exploration is required
Identification of all 4 glands	Essential — must find and inspect all 4 glands. Difficulty arises with ectopic glands or supernumerary glands
Cervical thymectomy	Should be performed routinely (or at least considered) to remove supernumerary glands that may reside in the thymus (recall: inferior parathyroids derive from the 3rd pharyngeal pouch and migrate with the thymus) ^[2]
Intraoperative PTH monitoring	Blood samples pre-incision and at intervals post-excision (5, 10, 15 min). Miami criteria: PTH drops to normal range + < 50% of the highest pre-incision or pre-excision value at 10 min post-resection ^[1]^[2]^[3]. In subtotal parathyroidectomy, the remnant will still produce PTH, so absolute normalisation is not expected — look for a significant drop (> 50%)
Frozen section	The resected half of the remnant gland is sent for frozen section to confirm the tissue is parathyroid (not fat, thyroid, or lymph node) ^[2]
Cryopreservation	Some centres cryopreserve parathyroid tissue at the time of total parathyroidectomy — can be used for delayed autotransplantation if the initial autograft fails ^[3]

Complication	Mechanism & Management
Hungry bone syndrome	Rapid, profound hypocalcaemia due to sudden drop in PTH → rapid deposition of calcium into demineralised bone that was previously being resorbed by excess PTH ^[2]. Typically occurs within 24–72 hours post-op. Presents with severe tetany, seizures, cardiac arrhythmia. Risk predicted by ↑ pre-op ALP (high ALP = highly active bone that will "soak up" calcium) ^[2]. Management: aggressive IV calcium gluconate infusion + oral calcium + vitamin D (calcitriol). May need days to weeks of IV calcium. Monitor Mg (often co-depleted)
Transient hypocalcaemia	After removal of hyperfunctioning glands, the remaining suppressed glands take time to "wake up" → transient hypoparathyroidism. Usually resolves within days to weeks ^[2]
Permanent hypoparathyroidism	Defined as requiring calcium/vitamin D supplementation > 1 year post-op ^[2]. Due to removal of too much parathyroid tissue or devascularisation of remnant. Risk is higher with total parathyroidectomy
Recurrent laryngeal nerve (RLN) injury	Unilateral → hoarseness (vocal cord paralysis). Bilateral → airway obstruction (both cords adducted) → emergency tracheostomy. Risk: ~1–2% for experienced surgeons. In re-operative surgery, risk is higher
Reactionary haemorrhage	Bleeding from the operative bed → expanding neck haematoma → airway compression. Emergency: open wound at bedside, evacuate clot, return to theatre
Persistent HPT (< 6 months post-op)	Due to missed pathology — supernumerary gland, ectopic gland, incomplete resection. Management: re-imaging (Sestamibi, 4D-CT), bilateral neck exploration ^[2]
Recurrent HPT (> 6 months post-op)	Due to missed pathology or parathyromatosis (disseminated parathyroid tissue from gland rupture during surgery) or regrowth of autograft/remnant ^[2]. Management: Sestamibi/SPECT-CT, selective venous sampling → re-operation

Routinely Check Calcium on Post-Op Day 1

After parathyroidectomy, routinely check Ca level on post-op Day 1 ^[2]. Hungry bone syndrome can be life-threatening if not anticipated. Patients with high pre-op ALP or large gland mass are at highest risk. Pre-operative calcium and vitamin D loading can help mitigate the severity.

Agent	Role	Details
Cinacalcet	First-line medical Mx when surgery is contraindicated or patient is unfit for surgery ^[1]^[2]^[3]	Activates CaSR → ↓ PTH secretion → ↓ serum calcium. Effective in lowering/normalising serum Ca but less consistent effect on serum PTH and no consistent effect on BMD ^[3]. Dose: 30–90 mg daily. Side effects: GI (nausea, vomiting), hypocalcaemia
Bisphosphonates	Adjunct for bone protection ^[2]	↓ Bone resorption → may help with bone pain and fracture risk. However, accumulate in CKD (renally cleared) → risk of adynamic bone disease with prolonged use. Generally avoided in severe CKD (eGFR < 30) unless bone biopsy confirms high turnover. Can be used post-transplant (eGFR usually improved)
Denosumab	Alternative anti-resorptive (RANKL inhibitor)	Unlike bisphosphonates, not renally cleared → can be used in CKD. However, risk of severe rebound hypercalcaemia when stopped → must not be discontinued abruptly. Limited data in tertiary HPT specifically
SERM (e.g., raloxifene)	Used in postmenopausal women with osteoporosis component ^[2]	Selective estrogen receptor modulator → ↓ bone resorption. Modest effect. Not a primary treatment for tertiary HPT

If a patient with tertiary HPT presents with severe symptomatic hypercalcaemia (corrected Ca > 3.5 mmol/L, or symptomatic at lower levels), this is a medical emergency requiring urgent treatment BEFORE definitive parathyroidectomy.

Step	Treatment	Mechanism	Notes
1. Aggressive IV saline hydration	0.9% NaCl at 200–500 mL/hr (adjust for cardiac status)	↑ GFR → ↑ renal Ca excretion. ↑ Na delivery to proximal tubule → ↓ Na-dependent paracellular Ca reabsorption. Also corrects dehydration (hypercalcaemia causes nephrogenic DI → polyuria → dehydration → concentrated blood → worsens hypercalcaemia) ^[1]	First-line therapy. Monitor fluid balance, CVP in cardiac patients
2. Loop diuretics (furosemide)	20–40 mg IV after adequate hydration	Inhibits Na⁺/K⁺/2Cl⁻ cotransporter in thick ascending limb → abolishes lumen-positive potential → ↓ paracellular Ca reabsorption → calciuresis. Also prevents fluid overload from aggressive saline	Only AFTER adequate hydration — giving furosemide to a dehydrated patient worsens hypercalcaemia by further concentrating the blood. Use in patients with heart failure or renal insufficiency to prevent fluid overload ^[1]
3. Calcitonin	Salmon calcitonin 4 IU/kg SC/IM Q12h	Directly inhibits osteoclastic bone resorption → ↓ Ca release from bone. Also ↑ renal Ca excretion. Rapid onset (hours)	Immediate short-term management ^[1]. Effect is modest and short-lived (tachyphylaxis develops within 48–72h due to receptor downregulation). Bridge to more definitive therapy
4. Bisphosphonates	Zoledronate 4 mg IV over 15 min OR Pamidronate 60–90 mg IV over 2–4h	Potent inhibitors of osteoclast function → ↓ bone resorption → ↓ Ca release. Onset of action: 2–4 days, peak at 4–7 days	Long-term management of hypercalcaemia due to excessive bone resorption ^[1]. Caution in severe CKD (accumulation, risk of osteonecrosis of jaw)
5. Cinacalcet	30–60 mg oral	Activates CaSR → ↓ PTH → ↓ Ca. Can be started immediately	Useful bridge to surgery
6. Dialysis (if on dialysis)	Low-calcium or calcium-free dialysate	Direct removal of calcium across the dialysis membrane	In dialysis-dependent patients, this is the fastest way to lower calcium. Effective but only temporary
7. Definitive surgery	Parathyroidectomy once medically stabilised	Removes the source of autonomous PTH	Should not be delayed excessively — surgery is the cure

PART 4: Monitoring and Follow-Up

Parameter	Frequency (KDIGO 2017)	Target
Serum Ca, PO₄	CKD 3: every 6–12 months. CKD 4: every 3–6 months. CKD 5/5D: every 1–3 months	Normal range
PTH	CKD 3: baseline then as needed. CKD 4: every 6–12 months. CKD 5/5D: every 3–6 months	CKD 3–5: within normal range. CKD 5D: 2–9× ULN
25-OH Vitamin D	Annually or after supplementation dose change	> 75 nmol/L (30 ng/mL)
ALP	Every 12 months (or more often if elevated PTH)	Monitor trends — persistent ↑ suggests high turnover
Bone density (DEXA)	If results will influence treatment decisions (KDIGO)	—

Parameter	Frequency	Notes
Serum Ca	Post-op Day 1 ^[2], then Q6–8h in immediate post-op period, then daily until stable	Watch for hungry bone syndrome (typically Day 1–3)
Serum Mg	Post-op Day 1 and as needed	Often co-depleted with Ca in hungry bone syndrome
PTH	Post-op Day 1, then periodically	Should be reduced. If persistently elevated → missed pathology
Long-term monitoring	Ca, PO₄, PTH every 3–6 months then annually when stable	Watch for recurrence (PTH rising + hypercalcaemia > 6 months post-op) or permanent hypoparathyroidism (requiring supplements > 1 year)

Feature	Secondary HPT	Tertiary HPT
First-line	Medical (phosphate binders, vitamin D, calcimimetics)	Surgical (if symptomatic/severe/impaired graft)
Surgery indicated when	Refractory to medical Mx (PTH > 800–1000, refractory hyperCa/hyperPO₄, progressive symptoms/calciphylaxis)	Persistent severe hypercalcaemia, impaired graft function, progressive symptoms ^[2]
Surgical procedure	Subtotal or total + autotransplantation (same options as tertiary)	Subtotal (3.5 resection) or total + autotransplantation or total without graft ^[2]
Medical alternative	Cinacalcet + vitamin D analogues + phosphate binders	Cinacalcet (if surgery unfit) ^[2]
Key post-op risk	Hungry bone syndrome ^[2]	Hungry bone syndrome, permanent hypoparathyroidism ^[2]

High Yield Summary — Management of Secondary & Tertiary HPT

Secondary HPT — Medical first:

Phosphate control: Diet restriction + phosphate binders (avoid calcium-based if vascular calcification; prefer sevelamer/lanthanum)
Vitamin D: Correct 25-OH-D deficiency first → then active analogues (calcitriol/alfacalcidol/paricalcitol) to suppress PTH
Calcimimetics (cinacalcet/etelcalcetide): for refractory secondary HPT on dialysis
Surgery only if refractory (PTH persistently very high, refractory hypercalcaemia/hyperphosphataemia, progressive symptoms)
KDIGO PTH target for CKD 5D: 2–9× ULN — do NOT over-suppress ^[4]

Tertiary HPT — Surgery is definitive:

Indications: persistent severe hypercalcaemia (> 6–12 months post-Tx), impaired graft function, progressive symptoms ^[2]
Options: Subtotal parathyroidectomy (3.5 resection) OR Total parathyroidectomy + autotransplantation (forearm brachioradialis or neck SCM) OR Total without graft (only if transplant unlikely) ^[2]
Intraoperative: Miami criteria (PTH drop > 50% + to normal at 10 min), frozen section of remnant ^[2]
Post-op: Check Ca Day 1 — watch for hungry bone syndrome (predicted by ↑ pre-op ALP). Rx: IV Ca gluconate + oral Ca + vitamin D ^[2]
Medical alternative: Cinacalcet if surgery contraindicated — controls Ca but less effect on PTH and BMD ^[3]
Post-op complications: Hungry bone syndrome, RLN injury, reactionary haemorrhage, transient/permanent hypoparathyroidism, persistent/recurrent HPT ^[2]

Active Recall - Management of Secondary & Tertiary HPT

References

^[1] Senior notes: felixlai.md (Medical treatment, surgical indications, focused parathyroidectomy, intraoperative PTH assay) ^[2] Senior notes: maxim.md (Tertiary HPT procedures, autotransplantation, subtotal parathyroidectomy, complications — hungry bone syndrome, persistent/recurrent HPT, RLN injury, permanent hypoparathyroidism, frozen section, cervical thymectomy, medical management) ^[3] Senior notes: Ryan Ho Endocrine.pdf (p43 — Surgical treatment indications JCEM 2014, cinacalcet mechanism and limitations, intra-op PTH assay Miami criteria, conservative Tx, cryopreservation) ^[4] Senior notes: Ryan Ho Urogenital.pdf (p107 — CKD-MBD pathogenesis, iatrogenic contributions, calcium-based binders, adynamic bone disease, over-treatment risks)

Complications of Secondary & Tertiary Hyperparathyroidism

Complications can be organised into three categories: (1) complications of the disease itself (from chronically elevated PTH, disordered calcium/phosphate, and vitamin D deficiency), (2) complications of treatment (both medical and surgical), and (3) complications of the underlying condition (CKD). Let's work through each systematically, always explaining why the complication occurs from first principles.

PART 1: Complications of the Disease Itself

These are the consequences of chronically elevated PTH, hypocalcaemia (secondary HPT), hypercalcaemia (tertiary HPT), hyperphosphataemia, and vitamin D deficiency — all components of CKD-MBD ^[4].

The skeleton is the organ hit hardest by secondary/tertiary HPT because it is the primary target of PTH action.

Complication	Pathophysiological Mechanism	Clinical Significance
Osteitis fibrosa cystica	The classical bone lesion of hyperPTH ^[3]. Continuously ↑PTH → excessive osteoclastic bone resorption (PTH acts on osteoblasts → RANKL → activates osteoclasts). The resorbed bone is replaced by fibrous tissue and collections of osteoclasts. Haemosiderin deposition from microhaemorrhages gives the brown colour → hence "brown tumours" — not true neoplasms but reactive lesions ^[3]	Bone pain, pathological fractures, deformity. Subperiosteal bone resorption (especially radial aspect of middle phalanges — pathognomonic), salt and pepper skull, bone cysts, tapering of distal clavicles ^[3]
Osteomalacia	↓ Vitamin D → ↓ calcium and phosphate for mineralisation → newly formed osteoid cannot mineralise properly. Historically also caused by aluminium deposition at the mineralisation front (from aluminium-containing phosphate binders — now rare) ^[4]	Deep, aching bone pain (different from the sharp pain of fractures). Looser zones (pseudofractures) on XR. Proximal myopathy. Vitamin D deficiency also directly impairs muscle function via VDR on skeletal muscle
Adynamic bone disease	Iatrogenic over-suppression of PTH by excessive vitamin D analogues or calcimimetics → PTH too low → insufficient osteoclast and osteoblast activity → bone cannot remodel → bone becomes brittle despite appearing mineralised ^[4]. Increasingly the most common form of renal osteodystrophy in the modern era	Paradoxically, patients fracture despite "adequate" mineralisation — the bone quality is poor because it cannot repair microdamage. Also, bone cannot buffer calcium (normally bone acts as a calcium reservoir) → episodes of hypercalcaemia after calcium loads
Mixed uraemic osteodystrophy	Combination of high turnover (osteitis fibrosa) and defective mineralisation (osteomalacia)	Features of both conditions simultaneously
Osteoporosis / Osteopenia	Continuously ↑PTH → cortical > trabecular bone resorption ^[3]. Cortical bone (hip, forearm) is more severely affected than trabecular bone (spine). 2–3× risk of vertebral, distal forearm, and pelvic fractures ^[3]	↓BMD more pronounced in cortical sites (forearm, hip) than trabecular sites (spine) — this is the opposite pattern to postmenopausal osteoporosis (where trabecular bone is preferentially lost). DEXA should include the distal 1/3 radius in HPT ^[3]
Pathological fractures	Weakened bone from any of the above mechanisms → fractures with minimal or no trauma	Vertebral compression fractures (height loss, kyphosis), hip fractures (high morbidity and mortality in CKD patients), rib fractures
Growth retardation (paediatric)	Chronic secondary HPT in children → disrupted growth plate function (impaired endochondral ossification from disordered calcium/phosphate/vitamin D) → renal rickets	Short stature, bowed legs, rachitic rosary (costochondral beading)

Why Cortical > Trabecular Bone Loss in Hyperparathyroidism?

PTH, when chronically elevated, preferentially activates remodelling at cortical (endosteal) bone surfaces → cortical thinning. In contrast, postmenopausal osteoporosis preferentially affects trabecular bone (oestrogen withdrawal → trabecular resorption). This is why DEXA of the distal 1/3 radius (almost pure cortical bone) is particularly important in hyperPTH — it may show significant BMD loss even when the spine (trabecular) is relatively preserved ^[3].

Complication	Pathophysiological Mechanism	Clinical Significance
Nephrolithiasis (kidney stones)	Hypercalciuria (from ↑PTH driving ↑Ca reabsorption in DCT, but filtered load exceeds reabsorptive capacity → net ↑ urinary Ca). Also ↑ urinary pH from PTH's bicarbonate-wasting effect → favours calcium phosphate precipitation. In some cases, calcium oxalate stones form	Renal colic (flank pain radiating to groin), haematuria. More relevant in tertiary HPT (hypercalcaemia → hypercalciuria) than secondary HPT (where patients may be anuric/oliguric on dialysis) ^[3]
Nephrocalcinosis	Chronic calcium-phosphate precipitation within the renal parenchyma (medullary interstitium) when Ca × PO₄ product is chronically elevated	Progressive renal impairment. In tertiary HPT post-transplant, nephrocalcinosis can damage the transplanted kidney → impaired graft function → this is one of the major indications for parathyroidectomy in tertiary HPT ^[2]
Tubular dysfunction	Chronic hypercalcaemia → direct tubular injury → impaired concentrating ability (nephrogenic DI), impaired acidification	Polyuria, polydipsia, distal renal tubular acidosis. Contributes to progressive CKD
Progressive CKD	Nephrocalcinosis + direct hypercalcaemic tubular injury → progressive decline in renal function. In post-transplant patients, this threatens graft survival	One of the strongest indications for surgical intervention in tertiary HPT ^[2]

This is the most clinically important category — cardiovascular disease is the #1 cause of death in CKD patients, and CKD-MBD is a major contributor.

Complication	Pathophysiological Mechanism	Clinical Significance
Vascular calcification	Chronically elevated Ca × PO₄ product → calcium-phosphate precipitation in arterial media (Mönckeberg's medial calcification) and intima (atherosclerotic plaque calcification). PTH, FGF-23, and phosphate all independently promote vascular smooth muscle cell transformation into osteoblast-like cells → active bone formation in vessel walls ^[4]	Coronary artery calcification → accelerated ischaemic heart disease → MI. Peripheral arterial calcification → peripheral arterial disease, amputation. Cardiac valve calcification → aortic stenosis, mitral regurgitation. Stiff, non-compressible vessels → falsely elevated ABI readings (can mask PAD)
Hypertension	Multiple mechanisms: (1) Hypercalcaemia → ↑ vascular smooth muscle contraction (Ca²⁺ is essential for smooth muscle contraction) → ↑ SVR. (2) Vascular calcification → ↓ arterial compliance → systolic hypertension. (3) CKD itself → volume overload, RAAS activation	Accelerates cardiovascular disease. LVH. Increases stroke and MI risk
Left ventricular hypertrophy (LVH)	Chronic hypertension → chronic pressure overload → concentric LVH. PTH also has direct myocardial effects — PTH receptors on cardiomyocytes → promotes hypertrophy and fibrosis independent of blood pressure	Cardiovascular: HTN, LVH, arrhythmia, intimal calcification ^[3]. LVH → diastolic dysfunction → HFpEF → heart failure
Cardiac arrhythmias	Hypocalcaemia → prolonged QT → risk of Torsades de Pointes. Hypercalcaemia → shortened QT, possible Osborn waves. Electrolyte disturbances (hyperkalaemia in CKD) compound the risk	Sudden cardiac death is a leading cause of mortality in dialysis patients
Calciphylaxis (Calcific uraemic arteriolopathy)	Calcification of dermal and subcutaneous arterioles → thrombosis → ischaemic skin necrosis ^[4]. Risk factors: ↑ Ca × PO₄ product, ↑ PTH, obesity, warfarin use (warfarin inhibits matrix Gla protein, which normally prevents vascular calcification), female sex, diabetes	Excruciatingly painful violaceous reticular skin lesions, typically on thighs, abdomen, buttocks → progress to necrotic eschar. Mortality up to 60–80% due to sepsis from wound infection. One of the most devastating complications of CKD-MBD. Treatment: urgent parathyroidectomy if HPT is a driver, wound care, sodium thiosulphate (chelates calcium), stop warfarin, non-calcium-based phosphate binders

Calciphylaxis: A Feared Complication

Calciphylaxis carries one of the highest mortality rates of any CKD-MBD complication. It is important to recognise it early — the initial skin lesions (livedo reticularis-like pattern, painful subcutaneous nodules) can be mistaken for cellulitis or DVT. Any CKD/dialysis patient with new painful skin lesions should be evaluated urgently. Biopsy (though risky — can worsen the wound) shows medial arteriolar calcification and thrombosis. Urgent measures include lowering the Ca × PO₄ product, stopping calcium-based binders, stopping warfarin, and considering parathyroidectomy if PTH is very high ^[4].

Complication	Pathophysiological Mechanism
Constipation	Hypercalcaemia (tertiary HPT) → ↓ smooth muscle excitability (Ca²⁺ stabilises cell membranes) → ↓ gut motility → constipation
Peptic ulcer disease	Hypercalcaemia → stimulates gastrin secretion from G cells → ↑ gastric acid → peptic ulceration
Pancreatitis	Hypercalcaemia → premature activation of trypsinogen to trypsin within the pancreas → autodigestion → pancreatitis. This is a recognised but uncommon complication of severe hypercalcaemia ^[3]
Anorexia, nausea, vomiting	Uraemia (CKD) + hypercalcaemia → direct CNS effects on vomiting centre + gastroparesis from smooth muscle dysfunction

Complication	Pathophysiological Mechanism
Chondrocalcinosis and pseudogout	↑ PTH → ↑ pyrophosphate production → calcium pyrophosphate dihydrate (CPPD) crystal deposition in articular cartilage → acute inflammatory arthritis (pseudogout). Also, chronic hypercalcaemia promotes calcium crystal deposition ^[3]
Gout	CKD → ↓ uric acid excretion → hyperuricaemia → urate crystal deposition
Periarticular calcification (tumoral calcinosis)	Chronically elevated Ca × PO₄ product → massive calcium-phosphate deposits in periarticular soft tissue → painful, large masses around joints (shoulders, hips, elbows)

Complication	Mechanism
Fatigue, cognitive impairment, depression	Multifactorial: hypercalcaemia (neuronal depression), uraemia, anaemia, vitamin D deficiency (VDR expressed in brain). Collectively termed "psychic overtones"
Uraemic encephalopathy	Late CKD → accumulation of uraemic toxins → diffuse cerebral dysfunction
Seizures	Severe hypocalcaemia (secondary HPT) → ↓ threshold for neuronal depolarisation → generalised seizures

PART 2: Complications of Treatment

Treatment	Complication	Mechanism
Active vitamin D analogues (calcitriol, alfacalcidol, paricalcitol)	Adynamic bone disease ^[4]	Over-suppression of PTH → insufficient bone remodelling → brittle bone → fractures. Also → inability to buffer calcium → hypercalcaemia episodes
	Hypercalcaemia and hyperphosphataemia	↑ Intestinal absorption of both Ca and PO₄ → worsens Ca × PO₄ product → vascular calcification
Calcium-based phosphate binders	Net positive calcium balance → hypercalcaemia → vascular calcification ^[4]	Calcium absorbed from binder exceeds what bone and kidney can handle → deposits in vessels
Cinacalcet	Hypocalcaemia (most important)	Over-activation of CaSR → excessive PTH suppression → ↓ Ca. Must monitor serum calcium closely after initiation and dose changes
	GI side effects (nausea, vomiting — up to 30%)	Direct GI irritation
	QT prolongation (rare)	Hypocalcaemia-mediated prolongation of phase 2 of cardiac action potential
Aluminium-containing phosphate binders (historical)	Aluminium toxicity — dialysis dementia (encephalopathy), osteomalacia, microcytic anaemia	Aluminium accumulates in brain (neurotoxic), bone (blocks mineralisation front), and marrow (impairs erythropoiesis). Largely abandoned ^[4]
Sevelamer	GI side effects (bloating, constipation, nausea)	Large polymer tablets cause mechanical GI symptoms. Pill burden is high
Bisphosphonates	Osteonecrosis of the jaw (rare), atypical femoral fractures (rare), accumulation in CKD	Bisphosphonates are renally cleared → accumulate in severe CKD → excessive bone suppression. Generally avoided if eGFR < 30
Denosumab	Severe rebound hypercalcaemia on cessation	RANKL inhibition wears off → sudden surge of osteoclast activity → massive bone resorption → severe hypercalcaemia. Must never be stopped abruptly — always transition to another antiresorptive

B. Complications of Surgical Treatment (Parathyroidectomy)

These are critically important for exams and clinical practice. They follow the same pattern as thyroidectomy complications but with unique features related to parathyroid-specific pathophysiology.

Complication	Mechanism & Details
Intraoperative bleeding	Parathyroid glands have a rich vascular supply from the inferior thyroid artery. Injury during dissection → bleeding
Recurrent laryngeal nerve (RLN) injury ^[1]^[2]^[12]	The RLN runs in the tracheo-oesophageal groove, intimately related to the parathyroid glands (especially the superior glands). Risk: ~1–2% in experienced hands, higher in re-operations. Unilateral RLN injury → vocal cord paralysis → hoarseness, ineffective cough, ↑ risk of aspiration pneumonia ^[1]^[12]. Bilateral RLN injury → bilateral vocal cord paralysis → airway obstruction (6 adductors > 2 abductors) → stridor, dyspnoea → emergency reintubation ± tracheostomy ^[1]^[12]
Superior laryngeal nerve (SLN) injury	External branch of SLN supplies the cricothyroid muscle (tenses the vocal cord for high-pitched sounds). Injury → loss of high pitch, vocal fatigue, poor volume ^[12]. Important to ask pre-operatively if the patient is a professional singer
Oesophageal / tracheal injury	Rare but possible during extensive dissection, especially in re-operative surgery

Complication	Mechanism & Details
Reactionary haemorrhage ^[2]	Bleeding from the operative bed → expanding neck haematoma → venous obstruction → acute laryngeal oedema → airway compromise. This is a surgical emergency. S/S: large, tense, firm, immobile neck swelling + SOB ^[12]. Management: cut subcuticular stitches and stitches holding strap muscles (evacuate all blood) at the bedside → call seniors for intubation → return to theatre ^[12]
Hungry bone syndrome ^[2]	Rapid, profound hypocalcaemia due to sudden drop in PTH, causing rapid deposition of Ca into demineralised bone ^[2]. Onset typically 24–72 hours post-op. Risk factors: very high pre-op PTH, ↑ pre-op ALP (indicates highly active bone that will "soak up" calcium) ^[2], large gland mass, severe bone disease. Management: Ca + vitamin D ^[2] — aggressive IV calcium gluconate infusion + oral calcium + calcitriol. May require days to weeks of IV calcium. Also replete magnesium (often co-depleted)
Transient hypocalcaemia ^[2]	After removal of hyperfunctioning glands, the remaining suppressed normal glands take time to recover → transient suppression of normal glands by the adenoma ^[2]. Usually resolves within days to weeks as remaining glands "wake up." Treated with temporary oral calcium ± vitamin D
Wound infection	Uncommon in clean surgical fields. Standard surgical wound care
Seroma	Fluid collection at operative site. Usually self-limiting

Complication	Mechanism & Details
Permanent hypoparathyroidism ^[2]	Defined as requiring Ca / vitamin D supplement 1 year post-op ^[2]. Due to removal of too much parathyroid tissue, devascularisation of remnant, or failure of autograft. Risk highest with total parathyroidectomy without autotransplantation. Management: lifelong oral calcium + calcitriol. Presents with perioral numbness, carpopedal spasm, Chvostek's sign, Trousseau's sign ^[12]. Severe hypoCa can lead to laryngospasm requiring emergency intubation / surgical airway ^[12]
Persistent hyperparathyroidism (< 6 months post-op) ^[2]	Due to missed pathology — supernumerary gland (in thymus or mediastinum), ectopic gland, incomplete resection. Management: re-imaging (Sestamibi/SPECT-CT) → bilateral neck exploration (BCE) ^[2]
Recurrent hyperparathyroidism (> 6 months post-op) ^[2]	Due to: (1) missed pathology (as above), (2) parathyromatosis — disseminated parathyroid tissue within the soft tissue of neck and mediastinum due to rupture of parathyroid gland during the operation ^[2] — these scattered fragments can proliferate and produce PTH. (3) Regrowth of remnant or autograft. Management: MIBI scan → BCE ^[2]
Hypertrophic scar / keloid formation	At the Kocher's incision site. More common in keloid-prone individuals (Asian populations including Hong Kong Chinese)

Post-Op Dyspnoea After Parathyroidectomy — Differential Diagnosis

If a patient develops dyspnoea after parathyroidectomy, consider these causes systematically ^[12]:

Haemorrhage → expanding haematoma → laryngeal oedema → airway obstruction. Look for tense neck swelling. Emergency: open wound at bedside.
Bilateral RLN injury → bilateral vocal cord paralysis → stridor → airway obstruction. Diagnosed by fibreoptic laryngoscopy.
Laryngospasm due to hypocalcaemia → check serum calcium urgently. Treat with IV calcium gluconate.
Tracheal injury / pneumothorax → rare, from surgical dissection.
Tracheomalacia → floppy tracheal wall due to chronic compression by large hyperplastic glands (rare in parathyroid surgery, more common after large goitre removal).

This table integrates all the major long-term consequences of poorly controlled secondary/tertiary HPT:

System	Complications	Key Mechanism
Bone	Osteitis fibrosa cystica, osteomalacia, adynamic bone disease, fractures, growth retardation	↑PTH → ↑ bone resorption; ↓ vitamin D → ↓ mineralisation; over-treatment → adynamic bone
Cardiovascular	Vascular calcification, coronary artery disease, LVH, valve calcification, calciphylaxis, hypertension	↑ Ca × PO₄ product, ↑ PTH, ↑ FGF-23 → vascular smooth muscle cell osteoblastic transformation
Renal	Nephrolithiasis, nephrocalcinosis, graft impairment (tertiary HPT)	Hypercalciuria, ↑ Ca × PO₄ product → crystal deposition
GI	Constipation, peptic ulcer, pancreatitis	Hypercalcaemia → ↓ smooth muscle motility, ↑ gastrin, trypsinogen activation
Joints	Pseudogout (CPPD), gout, tumoral calcinosis	↑ PTH → ↑ pyrophosphate; ↑ Ca × PO₄ → periarticular calcification
Neuropsychiatric	Depression, cognitive impairment, seizures (hypocalcaemia)	Hypercalcaemia → CNS depression; hypocalcaemia → neuronal hyperexcitability
Skin	Pruritus, calciphylaxis	Ca-PO₄ microprecipitation in skin; arteriolar calcification + thrombosis
Haematological	Anaemia (CKD-related, not directly from HPT), myelofibrosis (rarely associated)	↓ EPO production (CKD), uraemic toxins suppress erythropoiesis

High Yield Summary — Complications of Secondary & Tertiary HPT

Disease complications:

Bone: Osteitis fibrosa cystica (brown tumours, subperiosteal resorption), osteomalacia, adynamic bone disease (iatrogenic), pathological fractures. Cortical > trabecular bone loss in HPT (opposite to postmenopausal osteoporosis) ^[3]
Cardiovascular: Vascular calcification (#1 killer in CKD), calciphylaxis (60–80% mortality), LVH, arrhythmias ^[3]^[4]
Renal: Nephrolithiasis, nephrocalcinosis, graft damage in tertiary HPT ^[2]
GI: Constipation, PUD, pancreatitis
Joints: Pseudogout (CPPD), tumoral calcinosis

Treatment complications:

Medical: Adynamic bone disease (from over-suppression of PTH), hypercalcaemia from vitamin D analogues and calcium-based binders, hypocalcaemia from cinacalcet ^[4]
Surgical:
- Hungry bone syndrome — profound hypocalcaemia post-op from rapid calcium deposition into demineralised bone. Predicted by ↑ pre-op ALP. Rx: IV Ca + vitamin D ^[2]
- RLN injury — unilateral = hoarseness; bilateral = airway obstruction ^[1]^[12]
- Reactionary haemorrhage — expanding neck haematoma → airway emergency → open wound at bedside ^[2]^[12]
- Permanent hypoparathyroidism — requiring supplements > 1 year post-op ^[2]
- Persistent HPT (< 6 mo) — missed pathology; Recurrent HPT (> 6 mo) — missed pathology or parathyromatosis (disseminated parathyroid tissue from gland rupture) ^[2]
- Routinely check Ca level on post-op Day 1 ^[2]

Active Recall - Complications of Secondary & Tertiary HPT

References

^[1] Senior notes: felixlai.md (Surgical procedures — total parathyroidectomy, subtotal, autotransplantation, cervical thymectomy, complications of thyroidectomy, hypocalcaemia management) ^[2] Senior notes: maxim.md (Specific complications — RLN injury, reactionary haemorrhage, hungry bone syndrome, transient/permanent hypoparathyroidism, persistent/recurrent HPT, parathyromatosis, tertiary HPT indications) ^[3] Senior notes: Ryan Ho Endocrine.pdf (p42 — Hyperparathyroid bone disease, osteitis fibrosa cystica, brown tumours, subperiosteal resorption, osteopenia cortical > trabecular, cardiovascular complications, renal complications, joint complications) ^[4] Senior notes: Ryan Ho Urogenital.pdf (p107 — CKD-MBD components, bone abnormalities, extraskeletal calcification, calciphylaxis, vascular calcification, adynamic bone disease, iatrogenic contributions) ^[12] Senior notes: Ryan Ho Endocrine.pdf (p22 — Thyroidectomy/parathyroidectomy complications: haematoma management, RLN injury bilateral vs unilateral, SLN injury, hypocalcaemia CATS GO NUMB, post-op dyspnoea DDx, hungry bone syndrome)

Secondary & Tertiary Hpt

Secondary & Tertiary Hyperparathyroidism

2. Epidemiology and Risk Factors

3. Anatomy and Function of the Parathyroid Glands

4. Etiology (Focus on Hong Kong)

Causes of Secondary HPT

5. Pathophysiology

6. Classification

7. Clinical Features

7A. Symptoms

7B. Physical Signs

Active Recall - Secondary & Tertiary HPT: Definition, Epidemiology, Pathophysiology, Clinical Features

Differential Diagnosis of Secondary & Tertiary Hyperparathyroidism

Detailed Differential Diagnosis

Active Recall - Differential Diagnosis of Secondary & Tertiary HPT

References

Diagnostic Criteria, Algorithm & Investigations for Secondary & Tertiary HPT

Investigation Modalities: Detailed Breakdown

Active Recall - Diagnosis of Secondary & Tertiary HPT

References

Management of Secondary & Tertiary Hyperparathyroidism

PART 1: Management of Secondary HPT

A. Phosphate Control — The Foundation of Treatment

B. Vitamin D Therapy

PART 2: Management of Tertiary HPT

B. Surgical Options for Tertiary HPT

PART 4: Monitoring and Follow-Up

Active Recall - Management of Secondary & Tertiary HPT

References

Complications of Secondary & Tertiary Hyperparathyroidism

PART 1: Complications of the Disease Itself

PART 2: Complications of Treatment

B. Complications of Surgical Treatment (Parathyroidectomy)

Active Recall - Complications of Secondary & Tertiary HPT

References

On this page

Secondary & Tertiary Hpt

1. Definition

2. Epidemiology and Risk Factors

Secondary HPT

Tertiary HPT

3. Anatomy and Function of the Parathyroid Glands

Gross Anatomy

Blood Supply

Histology

PTH Physiology — What PTH Does

Calcium-Sensing Receptor (CaSR)

4. Etiology (Focus on Hong Kong)

Causes of Secondary HPT

A. Chronic Kidney Disease (CKD) — The Dominant Cause in Hong Kong

B. Vitamin D Deficiency

C. Calcium Malabsorption / Deficiency

D. Phosphate Excess

Causes of Tertiary HPT

5. Pathophysiology

5A. Pathogenesis of Secondary HPT in CKD (Step-by-Step)

5B. Transition from Secondary to Tertiary HPT

5C. CKD-Mineral and Bone Disorder (CKD-MBD) [4]

6. Classification

By Underlying Mechanism

By Bone Histology (Renal Osteodystrophy Classification — TMV System)

7. Clinical Features

7A. Symptoms

Bone-Related Symptoms

Symptoms of Hypocalcaemia (More Prominent in Secondary HPT)

Symptoms of Hypercalcaemia (More Prominent in Tertiary HPT)

Other Symptoms

7B. Physical Signs

Signs Related to Bone Disease

Signs of Hypocalcaemia (Secondary HPT)

Signs of Hypercalcaemia (Tertiary HPT)

Signs Related to Vascular/Soft Tissue Calcification (CKD-MBD)

Signs Specific to the Neck (Relevant in Tertiary HPT / Surgical Consideration)

8. Relevant Radiological Findings (Not Diagnostic Criteria — Just Clinical Features)

9. Key Biochemical Patterns — A Summary Table

Active Recall - Secondary & Tertiary HPT: Definition, Epidemiology, Pathophysiology, Clinical Features

References

The Core Diagnostic Question

Differential Diagnosis Algorithm

Detailed Differential Diagnosis

A. Differentials for Elevated PTH with Low/Normal Calcium (i.e., DDx of Secondary HPT)

B. Differentials for Elevated PTH with High Calcium (i.e., DDx of Tertiary HPT)

C. Differentials for Hypocalcaemia in CKD (Beyond Secondary HPT)

D. Differentials for Bone Disease in CKD (Beyond Renal Osteodystrophy)

Approach to Differentiating Secondary vs Tertiary HPT — A Practical Summary

Active Recall - Differential Diagnosis of Secondary & Tertiary HPT

Important Framing: There Are No "Diagnostic Criteria" in the Traditional Sense

Diagnostic Definitions (Working Criteria)

KDIGO Target Ranges for Secondary HPT in CKD (2017 Updated Guidelines)

Diagnostic Algorithm

Investigation Modalities: Detailed Breakdown

A. First-Line Biochemical Investigations

B. Second-Line Biochemical Investigations

C. Investigations to Screen for Complications of Secondary/Tertiary HPT

D. Localisation Studies (Pre-operative — Primarily for Tertiary HPT When Surgery Is Planned)

E. Intraoperative Investigations

F. Bone Biopsy (Rarely Performed — Gold Standard for Renal Osteodystrophy Classification)

Comprehensive Biochemical Comparison Table (Diagnostic Aid)

Summary of Stepwise Diagnostic Approach

Active Recall - Diagnosis of Secondary & Tertiary HPT

Management Algorithm Overview

PART 1: Management of Secondary HPT

A. Phosphate Control — The Foundation of Treatment

1. Dietary Phosphate Restriction

2. Phosphate Binders

B. Vitamin D Therapy

1. Nutritional Vitamin D (Cholecalciferol / Ergocalciferol)

2. Active Vitamin D Analogues

C. Calcimimetics

D. Optimise Dialysis

E. Other Medical Measures

F. Parathyroidectomy for Refractory Secondary HPT

PART 2: Management of Tertiary HPT

A. When to Intervene

B. Surgical Options for Tertiary HPT

Surgical Approach and Intraoperative Considerations